Tenax Therapeutics releases LEVEL clinical trial results presentation

Reuters2026/09/09 12:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tenax Therapeutics posted a presentation detailing Phase 3 LEVEL trial results for TNX-103 (levosimendan) in PH-HFpEF.
Primary endpoint missed: 6-minute walk distance improved 14 m on TNX-103 vs 10.4 m on placebo; treatment difference 3.5 m (p=0.63).
Prespecified subgroup below median baseline 6MWD (<333 m) showed a 26.3 m placebo-adjusted improvement; 95% CI 6.0 to 46.7.
NT-proBNP fell 49% in the study; RVSP declined 3.5 mmHg, supporting a bi-ventricular hemodynamic effect.
Company framed the neutral topline result as a patient-selection issue; plans to reshape LEVEL-2 to enrich for more impaired patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to the latest client fund flow data from Bank of America, last week its clients recorded a net purchase of U.S. stocks for the second consecutive week, with the inflow reaching the highest level since mid-July. This marks the sixth largest single-week net inflow since the bank began tracking weekly data in 2008.

智通财经•2026/09/09 16:16